Research programme: epoxide-hydrolase-inhibitors therapeutics - EicOsis
Latest Information Update: 10 Dec 2025
At a glance
- Originator EicOsis
- Class Antidementias; Antihaemorrhagics; Cardiovascular therapies
- Mechanism of Action Epoxide hydrolase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Alzheimer's disease
Most Recent Events
- 05 Aug 2025 Early research in Alzheimer's disease in USA (PO), prior to August 2025 (EicOsis pipeline, August 2025)